The effect of transurethral resection of the prostate on PSA, F/T PSA Ratio and PSA Density in patients whose PSA levels are between 2,5-10 ng/mL

Year 2012, Volume: 7 Issue: 3, 16 - 21, 01.08.2012

Evrim Emre Aksoy Tansu Değirmenci Adil Emrah Sonbahar Salih Budak Zafer Kozacıoğlu Bülent Günlüsoy Süleyman Minareci Ali Rıza Ayder

Abstract

Objective: In this study, we aimed to evaluate the effect of the transurethral resection of the prostate on PSA, f/t PSA ratio, PSAD and the usefulness of these markers for cancer detection after the operation in patients who had 2.5-10 ng/mL PSA level.. Materials and Methods: A total of 50 patients who underwent TUR-P in our clinic were evaluated. Patients who had PSA levels between 2,5-10 ng/mL with benign pathology after needle biopsies and the age between 50-70 were included in the study. Blood PSA level, f/tPSA ratio and PSA density were calculated in preoperative period, postoperative third and sixth months. The resected prostate volumes were calculated from the difference between preoperative and postoperative third month prostate volumes. In this way the mean PSA, mean f/t PSA ratio and mean PSAD between preoperative, postoperative third and sixth month were compared. Results: Mean age value was 61,82 ± 4,11 53-69 years . Postoperative 3. month PSA and PSAD levels were lower than preoperative PSA and PSAD levels and it was statistically significant p=0,041, p 0,001 . But there was no significant difference between postoperative third and sixth month for PSA and PSAD levels p=0,348, p=0,550 . On the other hand there was no significant difference between preoperative, postoperative third and sixth month f/ tPSA ratio p=0,954; p=0,200 . Conclusion: The usefulness of the markers such as PSA and PSAD for prostate cancer detection is limited because of low levels in postoperative period. On the other hand, because of there is no change in f/tPSA ratio, this ratio can be used as a marker of cancer detection in this new population.

Keywords

BPH , PSA , TUR-P , PSAD , f/t PSA

PSA’sı 2,5-10 ng/ml arasında olan BPH tanılı hastalarda transüretral prostat rezeksiyonunun PSA, serbest/total PSA oranı, PSA dansitesi düzeyleri üzerindeki etkinliği

Abstract

Amaç: Bu çalışmada PSA’sı 2,5-10 ng/mL olan hastalarda TUR-P’nin, PSA, f/t PSA oranı ve PSAD üzerindeki etkilerini inceleyerek postop dönemde bu markerların kanser taramasındaki kullanılabilirliğini değerlendirdik. Gereç ve Yöntemler: PSA değerleri 2,5-10 ng/mL arasında olan, prostat biyopsisi patolojileri benign olan, BPH tanısıyla kliniğimzde TUR-P uygulanan 50-70 yaş arası 50 erkek hasta çalışmaya dahil edildi. Hastaların preop, postop 3. ay ve postop 6. ay PSA, f/tPSA oranı ve PSAD’leri hesaplandı. Preop ölçülen prostat hacminden postop 3. aydaki prostat hacmi çıkarılarak rezeke edilen doku miktarları hesaplandı. Bu veriler kullanılarak hastaların serum PSA. f/tPSA ve PSAD’lerinin preoperatif, postoperatif 3. ay ve postoperatif 6. ay değerleri istatistiksel olarak karşılaştırıldı. Bulgular: Hastaların yaş ortalaması 61,82 ± 4,11’di. Postop 3. ay PSA değerleri, preop PSA değerlerine göre düşük olarak izlenirken aralarındaki fark istatistiksel olarak anlamlıydı p=0,041 . Benzer şekilde postop 3. ay PSAD’leri, preop PSAD’lerine göre anlamlı derecede düşük olarak izlendi p 0,001 . PSA ve PSAD’nin postoperatif 3. ve 6. ay değerleri arasında anlamlı farklılık izlenmedi p=0,348 p=0,55 . Preop, postop 3. ay ve postop 6. ay f/ tPSA oranları arasında da anlamlı bir farklılık izlenmedi p=0,954; p=0,2 . Sonuç: BPH tanısıyla TUR-P uygulanan hastalarda postop dönemde özellikle PSA ve PSAD’de düşüş olması, bu markerların bu hasta popülasyonunda kanser taraması amacı ile kullanımını sınırlamaktadır. F/T PSA oranı ise bu hasta popülasyonunda kanser taraması amacıyla kullanılabilecek güvenilir bir tetkik olarak gözükmektedir.

Keywords

BPH , PSA , TUR-P , PSAD , f/t PSA

References

• Fong YK, Milani S and Djavan B. Natural history and cli- nical predictors of clinical progression in benign prostatic hyperplasia. Curr Opin Urol 2005; 15:35-38.
• Thorpe A and Neal D. Benign prostatic hyperplasia. Lancet 2003;361 (9366):1359-1367.
• Roehrborn CG. Boyle P, Gould AL, Waldstreicher J. Serum prostate- specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.Urology 999;53(3):581-89.
• Wright EJ, Fang J, Metter EJ, et al. Prostate specific anti- gen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging. J Urol. 2002; 167(6):2484-87.
• Recker F. Free to total PSA ratio improves the specifity for detecting prostate cancer in patients with prostatism and intermediate PSA levels. Br. J Urol. 1998;81:532-8.
• Freedland SJ, Sutter ME, Dorey F, et al: Defining the ide- al cutpoint for determining PSA recurrence after radical prostatektomy. Urology 2003; 61:365-9.
• Littlejohn JO Jr, Ghafar MA, Kang YM, Kaplan SA, Tran- surethral resection of the prostate: the new old standart. Curr Opin Urol. 2002;12:19-23.
• Coker CB, Coptcoat MJ, Mulvin A, et al. The release of free prostate specific antigen into the circulation during tran- surethral resection of the prostate: Kinetics and interaction with serum protease inhibitors. Br J Urol. 1998;81:105-8.
• Wolff JM, Boekels O, Borchers H, et al. Altered prostate specific antigen reference range after transurethral resecti- on of the prostate. Anticancer Res 2000; 20:4977-80.
• Mc Neal Je: Regional morphology and pathology of the prostate. Am J Clin Pathol. 1968 ; 49(3): 347-57.
• Lepor H, Nıeder A, Feser J, et al. Total prostate and tran- sition zone volumes and transition zone index are poorly correlated with objective measures of clinical benign pros- tatic hyperplasia. J Urol. 1997;158:85-8.
• Bonilla JRC, MC Connel JD. Pattern of prostate growth observed in placebo treated patients in the PLEES trial over four years. J Urol. 1995;159(5):301.
• Marks LS, Dorey FJ, Rhodes T, et al. Serum prostate speci- fic antigen levels after transurethral resection of prostate: A longitudinal characterization in men with benign prostatic hyperplasia. J Urol,1996;156: 1035-38.
• Stamey TA, Yang N, Hay AR, et al: Prostate specific antigen as a serum maker for adenocarcinoma of the prostate. New Engl J Med 1987; 317: 909-16.
• Loyd SN, Collins GN, McKelvie GB, Heir M, Rogers AC. Predicted and actual change in serum PSA following pros- tatectomy for BPH. Urology 1994;43:472-9.
• Aus G, Bergdahi S, Hugosson J,et al. Volume determina- tions of the whole prostate and of adenomas by transrec- tal ultrasound in patients with clinically benign prostatic hyperplasia: Correlation on of resected weight, blood loss and duration of operation Br J Urol 1994;73:65963.
• Recker F. Kwiatowski M. Petterson K. Pironen T. Lümen G. Huber A. Tscholl R. Enhanced expression of prostate- specific antigen in the transition zone of the prostate. Eur Urol 1998;33:549-55.
• Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum PSA in a community based population of healthy men : Estab- lishment of age specific reference ranges. JAMA1993;270 (7):860-4.
• Benson MC, Whang IS, Olsson CA, et al. The use of prosta- te specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen J Urol. 1992;147:817-21.
• McConnel JD, Bruskewitz R, Walsh P, et al. The effect of fi- nasteride on the risk of acute urinary retention and need for surgical treatment among men with benign prosta- tic hyperplasia. Finasterid Long-Term Efficacy an Safety Study Group. N Engl J Med. 1998;338(9):557-63.